Life Sciences

  • January 13, 2026

    US Patent Applications Plunge After Years Of Growth

    The number of patent applications filed in the U.S. dropped 9% in 2025 to the lowest level since 2019 after seven years of growth, and the number of granted applications also declined slightly, according to a report released Tuesday.

  • January 13, 2026

    Squires Institutes 8 Patent Reviews, Rebuffs 47 Petitions

    U.S. Patent and Trademark Office Director John Squires has denied 47 requests for America Invents Act patent reviews and granted eight other petitions, continuing his practice of spurning most patent challenges that reach his desk since he took over the handling of institution decisions.

  • January 13, 2026

    Beasley Allen Talc Work Sends 'Bad Signal,' J&J Says

    Johnson & Johnson's talc unit told a New Jersey appeals panel on Tuesday that a lower court's ruling permitting Beasley Allen Law Firm attorneys to represent plaintiffs in multicounty litigation over its talc-based baby powder "sends a very bad signal" to the state bar.

  • January 13, 2026

    Express Scripts Can't Impel FTC Atty Views On Insulin Makers

    A Federal Trade Commission in-house judge has denied a bid from Express Scripts to force a commission attorney to sit for a deposition to discuss an investigation into insulin manufacturers as the pharmacy benefit manager defends against the agency's insulin pricing case.

  • January 13, 2026

    J&J Wins Partial Reversal Of $1B Merger Milestone Loss

    Delaware's Supreme Court has partially reversed a vice chancellor's September 2024 ruling that Johnson & Johnson owes more than $1 billion for failing to prioritize regulatory approvals linked to "earnout" payments for robotic surgical device technology that J&J acquired from a developer.

  • January 12, 2026

    CareFirst Opposes J&J's Bid To Revisit Stelara Antitrust Case

    Insurer CareFirst urged a Virginia federal court to reject Johnson & Johnson's bid for reconsideration of a ruling that refused to toss antitrust and patent fraud claims over the immunosuppressive drug Stelara.

  • January 12, 2026

    The Curious, Very Long Delay In A Pioneering Drug Prices Suit

    When Merck & Co. launched a fiery challenge to Medicare's landmark drug price negotiations, it blazed a trail for many similar suits. But 31 months later, the challenge is stalled where it started as Merck begs for a ruling, other suits speed along the path it created and huge costs now seem unavoidable.

  • January 12, 2026

    Del. Jurist Cites 'Troubling' Questions In Cashout Suit

    A Delaware vice chancellor described as "troubling" on Monday unsettled questions in a stockholders' amended suit alleging an unfair recapitalization that allegedly forced out Bioventix Inc. common stockholders for a penny per share ahead of a new financing, asking how much discovery had been taken before filing of the complaint.

  • January 12, 2026

    Terumo Plaintiff Settles, Drops Cancer Case Before Trial

    One of the two plaintiffs set to take their case to trial this month against Terumo BCT Inc. accusing the company of causing their cancer reached a stipulation to dismiss his case with prejudice Friday, according to court records.

  • January 12, 2026

    Del. Court Blocks Presuit Damages On Agilent Patent

    A Delaware federal court ruled that laboratory equipment company Agilent Technologies couldn't collect damages for any alleged infringement of one of its patents prior to the filing of its intellectual property lawsuit against biotechnology business Axion BioSystems.

  • January 12, 2026

    Feds To Drop Appeal In 340B Rebate Pilot Challenge

    The U.S. Department of Health and Human Services on Monday suggested it will end its appeal of a First Circuit order temporarily blocking it from instituting a rebate program that would change how the agency distributes payments in the federal 340B drug discount program that provides medications at reduced costs to low-income Americans. 

  • January 12, 2026

    Sidley-Led Smith & Nephew Inks $450M Orthopaedics Deal

    Sidley Austin-advised Smith & Nephew said Monday it will acquire Gunderson Dettmer-led U.S. sports medicine company Integrity Orthopaedics and its Tendon Seam rotator cuff repair technology in a deal valued at up to $450 million.

  • January 12, 2026

    Medicine Biz Mirador Wraps $250M Funding Round

    San Diego-based clinical-stage precision medicine company Mirador Therapeutics Inc. announced Monday that it closed its Series B funding round with $250 million of investor commitments, bringing the company's total capital raised since its March 2024 launch to more than $650 million.

  • January 12, 2026

    Justices Want SG Input On Arthritis Drug Competition Fight

    The U.S. Supreme Court on Monday asked the Trump administration to weigh in on whether state unfair competition claims should be used to block a competitor from selling compounded versions of drugs in certain states.

  • January 12, 2026

    No High Court Review For California Opioid 'Nuisance' Suit

    The U.S. Supreme Court on Monday said it would not weigh in on a circuit court decision that a California public nuisance lawsuit against pharmacy benefit managers over their opioid-dispensing practices belongs in state court.

  • January 12, 2026

    Justices Won't Weigh Collective Cert. Process In Eli Lilly Case

    The U.S. Supreme Court declined on Monday to review whether courts should stick with a long-standing two-step analysis for certifying collective actions in an age discrimination case against Eli Lilly and Co. that could have affected wage and hour litigation.

  • January 09, 2026

    Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims

    A Connecticut federal judge on Friday refused to hand a quick win to Mylan Pharmaceuticals and Aurobindo Pharma USA in sprawling antitrust litigation against 26 total pharmaceutical companies, ruling that a coalition of states has enough evidence to raise a genuine dispute about whether the companies conspired to fix drug prices.

  • January 09, 2026

    Squires Sets Precedent, Guidance On Discretionary Denials

    U.S. Patent and Trademark Office Director John Squires on Friday designated four decisions on discretionary denials at the Patent Trial and Appeal Board precedential and another nine informative.

  • January 09, 2026

    Biopharma Co. Secures D&O Coverage For Shareholder Suit

    A biopharmaceutical company is entitled to coverage for a suit alleging its board breached fiduciary duties under a pair of primary and excess directors and officers policies, a Delaware state court ruled, saying the suit is "meaningfully linked" to a previously noticed demand for books and records.

  • January 09, 2026

    Veterinary Group Says DOJ Accreditation Points Irrelevant

    The American Veterinary Medical Association has told a Tennessee federal court that the government's concerns about professional groups are irrelevant to a veterinary school's antitrust case challenging the association's accreditation requirements.

  • January 09, 2026

    Judge Denies 'Fatally Untimely' Bid For New Poaching Trial

    A Boston federal judge has denied what she called a "fatally untimely" motion for a new trial after a jury handed Cynosure LLC a $25 million verdict against two former employees who the company said caused other employees to breach their noncompete and nonsolicitation agreements.

  • January 09, 2026

    Judge Blocks Edwards' $945M Heart Valve Deal

    A D.C. federal judge issued an order on Friday preventing Edwards Lifesciences Corp. from moving ahead with its planned $945 million deal for JenaValve Technology Inc., torpedoing the merger challenged by the Federal Trade Commission.

  • January 09, 2026

    4 Argument Sessions That Benefits Attys Should Watch In Jan.

    The U.S. Supreme Court will zero in on the methodology for assessing liability for pulling out of a multi-employer pension fund, and the circuit courts will hear bids to revive suits over alleged 401(k) mismanagement and deferred compensation. Here, Law360 looks at a quartet of oral arguments coming up in January.

  • January 09, 2026

    How New Judges Can Quell Patent Litigation Fears

    Patent litigation has a reputation for being particularly complex due to its technical content, which can be intimidating for litigants, attorneys and judges alike. In the first of a two-part series, several judges in the trenches of patent law spoke with Law360 about how new judges can make patent litigation less overwhelming.

  • January 09, 2026

    Ex-Prosecutor OK For Drug Pricing MDL, Special Master Says

    Former Connecticut Assistant Attorney General Joseph Nielsen and his law firm, Lowey Dannenberg PC, should not be disqualified from representing insurers in multidistrict litigation over generic drug price-fixing because he did not have any special knowledge that the states suing drugmakers hadn't already shared with the private plaintiffs, according to a special master's report and recommendation.

Expert Analysis

  • What's Changing For Cos. In New Calif. Hazardous Waste Plan

    Author Photo

    While the latest hazardous waste management plan from California's Department of Toxic Substances Control still awaits final approval, companies can begin aligning internal systems now with the plan's new requirements for environmental justice, waste and disposal reduction, waste criteria, and capacity planning, says Thierry Montoya at Frost Brown.

  • Fed. Circ. In September: The Printed Matter Doctrine Expands

    Author Photo

    The Federal Circuit’s recent decision in Bayer v. Mylan represents an extension of the doctrine that adding new words to an existing product or method will not support patentability unless there is a functional relationship, bringing new considerations for both patent holders and challengers, say attorneys at Knobbe Martens.

  • Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split

    Author Photo

    In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.

  • Series

    Practicing Stoicism Makes Me A Better Lawyer

    Author Photo

    Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.

  • Broader Eligibility For AI-Related Patents May Be Coming

    Author Photo

    A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick.

  • Series

    The Biz Court Digest: Texas, One Year In

    Author Photo

    A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.

  • AI Product Safety Insights May Expand Foreseeability

    Author Photo

    Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain.

  • Series

    Law School's Missed Lessons: Educating Your Community

    Author Photo

    Nearly two decades prosecuting scammers and elder fraud taught me that proactively educating the public about the risks they face and the rights they possess is essential to building trust within our communities, empowering otherwise vulnerable citizens and preventing wrongdoers from gaining a foothold, says Roger Handberg at GrayRobinson.

  • Organ Transplant System Reforms Mark Regulatory Overhaul

    Author Photo

    Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.

  • Adapting To USPTO's Reduction Of Examiner Interview Time

    Author Photo

    Reported changes to the U.S. Patent and Trademark Office's examiner performance appraisal plan will likely make interviews scarcer throughout the application process, potentially influencing patent allowance rates and increasing the importance of approaching each interview with a clear agenda and well-defined goals, say attorneys at Polsinelli.

  • Federal Grantees May Soon Face More Limitations On Speech

    Author Photo

    If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable.

  • 5 Crisis Lawyering Skills For An Age Of Uncertainty

    Author Photo

    As attorneys increasingly face unprecedented and pervasive situations — from prosecutions of law enforcement officials to executive orders targeting law firms — they must develop several essential competencies of effective crisis lawyering, says Ray Brescia at Albany Law School.

  • Anticipating FTC's Shift On Unfair Competition Enforcement

    Author Photo

    As the Federal Trade Commission signals that it will continue to challenge unfair or deceptive acts and practices under Section 5 of the FTC Act, but with higher evidentiary standards, attorneys counseling healthcare, technology, energy or pharmaceuticals clients should note several practice tips, says Thomas Stratmann at George Mason University.

  • Insights From Recent Cases On Navigating Snap Removal

    Author Photo

    Snap removal, which allows defendants to transfer state court cases to federal court before a forum defendant is properly joined and served, is viewed differently across federal circuits — but keys to making it work can be drawn from recent decisions critiquing the practice, say attorneys at Perkins Coie.

  • Opinion

    It's Time For The Judiciary To Fix Its Cybersecurity Problem

    Author Photo

    After recent reports that hackers have once again infiltrated federal courts’ electronic case management systems, the judiciary should strengthen its cybersecurity practices in line with executive branch standards, outlining clear roles and responsibilities for execution, says Ilona Cohen at HackerOne.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.